▼Interferon beta-1b - Hope or hype?

Drug and Therapeutics Bulletin

Volumn 34, Issue 2, 1996, Pages 9-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; INTERFERON BETA SERINE; RECOMBINANT BETA INTERFERON;

CHILL; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; FATIGUE; FEVER; HEADACHE; HUMAN; LYMPHOCYTOPENIA; MALAISE; MULTIPLE SCLEROSIS; MUSCLE STIFFNESS; MYALGIA; NAUSEA; NEUTROPENIA; SHORT SURVEY; SKIN MANIFESTATION;

CLINICAL TRIALS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS;

EID: 0030057683     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1996.3429     Document Type: Article

References (17)

1. Standing Medical Advisory Committee. New Drugs for Multiple Sclerosis. NHS Executive, Headquarters November 1995.
2. ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994; 343: 271-5.
3. Paty DW, Oger JJF, Kastrukoff LF et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180-5.
4. 2-weighted brain MRI activity in multiple sclerosis. A follow-up study. Neurology 1995; 45: 255-60.
5. Panitch HS, Sever, Jr CR. Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimmunol 1993; 46: 155-64.
6. Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214: 1026-8.
7. Jacobs L, Salazar AM, Herndon R et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986; ii: 1411-3.
8. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; i: 893-5.
9. Camenga DL, Johnson KP, Alter M et al. Systemic recombinant α-2 interferon therapy in relapsing multiple sclerosis.
10. Durelli L, Bongioanni MR, Cavallo R et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406-13.
11. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
12. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
13. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Inteferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
14. Drug costs and treatment choices: a DTB symposium. DTB 1993; 31: 41-1.
15. Goodkin DE. Interferon beta-1b. Lancet 1994; 344: 1057-60.
16. Goodkin DE. Interferon beta-1b. Lancet 1994; 344: 1702-3.
17. Committee for Proprietary Medicinal Products. European Public Assessment Report(EPAR). Betaferon, London: European Agency for the Evaluation of Medicinal Products, 1995.